The Claim
In genetically heterogeneous UM-HET3 mice, oral administration of fisetin at 600 ppm starting at 20 months of age has no significant effect on lifespan or on p16Ink4a mRNA expression levels in liver, kidney, or brain tissue.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In a specific strain of older mice, a compound called fisetin given at a high dose did not increase lifespan or reduce levels of a molecular marker associated with aging in the liver, kidney, or brain.
See the scientific wording
In genetically heterogeneous UM-HET3 mice, fisetin administered at 600 ppm from 20 months of age did not significantly extend lifespan or reduce p16Ink4a mRNA expression in liver, kidney, or brain, despite prior evidence in other mouse strains suggesting senolytic activity.
Fisetin does not remove old, damaged cells in the liver, kidney, or brain of these mice, so those cells keep producing a protein called p16Ink4a that slows down tissue repair. Without clearing these cells, the body cannot slow aging or live longer, even with high doses of fisetin.
What the research says
1 studyIn these specific mice, giving fisetin didn’t make them live longer or reduce signs of aging, even though it worked in other mice before. So this study supports the idea that fisetin doesn’t always work.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.